Health Care • Biotechnology: Pharmaceutical Preparations
$0.75 ▼ -0.03
(-3.86%)
MKT CAP: $2.6M • VOL: 30.0K
52W L $1 52W H $8
ROARABLE / RQD
D- • 39/100
PIOTROSKI
3 / 9
PRFX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $17.0K | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | -$53.0K | — | — |
| Gross Margin % | -50.0% | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$5.1M | -$14.7M | -$9.6M |
| Operating Margin % | -80.0% | — | — |
| Net Income (GAAP) | -$5.0M | -$14.6M | -$9.3M |
| EBITDA (Normalized) | -$5.1M | -$14.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$4.0M | -$12.6M | -$6.7M |
| Capital Expenditures (CapEx) | $2.0K | $13.0K | — |
| Free Cash Flow (FCF) | -$4.0M | -$12.6M | -$6.7M |
| FCF Margin % | -80.0% | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $3.1M | $4.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $8.5M | $1.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PRFX.